

Maria Teresa Fulciniti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3081320/publications.pdf>

Version: 2024-02-01

93
papers

3,625
citations

293460

24
h-index

162838

57
g-index

93
all docs

93
docs citations

93
times ranked

6413
citing authors

#	ARTICLE	IF	CITATIONS
1	Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. <i>Haematologica</i> , 2022, 107, 1410-1426.	1.7	6
2	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	13.9	173
3	Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. <i>Nature Communications</i> , 2021, 12, 868.	5.8	173
4	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483.	2.6	64
5	Detection of minimal residual disease by next generation sequencing in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 117.	2.8	6
6	CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. <i>Methods in Molecular Biology</i> , 2021, 2348, 189-204.	0.4	12
7	B Cell Transcriptional Coactivator <i>POU2AF1</i> (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication. <i>Blood</i> , 2021, 138, 2670-2670.	0.6	2
8	IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. <i>Blood</i> , 2021, 138, 1980-1985.	0.6	11
9	Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu. <i>Blood</i> , 2021, 138, 2686-2686.	0.6	0
10	Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021, 138, 545-545.	0.6	1
11	Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells. <i>Blood</i> , 2021, 138, 2655-2655.	0.6	7
12	Dysfunctional HDAC8 Impacts Genomic Integrity and Is a Novel Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1610-1610.	0.6	0
13	Chromatin Remodeling and Associated Changes in Gene Expression Induced By Bone Marrow Stromal Cells Identify Features of High-Risk Multiple Myeloma. <i>Blood</i> , 2021, 138, 2672-2672.	0.6	0
14	Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability. <i>Blood</i> , 2021, 138, 2687-2687.	0.6	0
15	Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma. <i>Blood</i> , 2021, 138, 894-894.	0.6	0
16	Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma. <i>Blood</i> , 2021, 138, 891-891.	0.6	2
17	The effects of MicroRNA deregulation on pre-mRNA processing network in multiple myeloma. <i>Leukemia</i> , 2020, 34, 167-179.	3.3	11
18	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3107-3118.	0.8	45

#	ARTICLE	IF	CITATIONS
19	YWHAE/14-3-3 μ expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. <i>Blood</i> , 2020, 136, 468-479.	0.6	8
20	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , 2020, 136, 4-5.	0.6	11
21	Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-14.	0.6	10
22	High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 2-2.	0.6	1
23	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. <i>Blood</i> , 2020, 136, 7-8.	0.6	4
24	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
25	Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models. <i>Blood</i> , 2020, 136, 21-22.	0.6	3
26	Exploring <i>POU2AF1</i> (<i>BOB-1</i>) Dependency and Transcription Addiction in Multiple Myeloma. <i>Blood</i> , 2020, 136, 49-49.	0.6	0
27	Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
28	Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma. <i>Blood</i> , 2020, 136, 40-40.	0.6	1
29	Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
30	Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition. <i>Blood</i> , 2020, 136, 33-34.	0.6	2
31	Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 369-377.	3.2	24
32	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	3.3	313
33	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019, 10, 3835.	5.8	183
34	Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. <i>Blood</i> , 2019, 134, 160-170.	0.6	41
35	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 39.	2.8	38
36	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. <i>Leukemia</i> , 2018, 32, 1948-1957.	3.3	179

#	ARTICLE	IF	CITATIONS
37	Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 422-430.	0.2	8
38	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. <i>Nature Genetics</i> , 2018, 50, 515-523.	9.4	163
39	Widespread intronic polyadenylation diversifies immune cell transcriptomes. <i>Nature Communications</i> , 2018, 9, 1716.	5.8	117
40	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). <i>Blood</i> , 2018, 132, 2778-2780.	0.6	18
41	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. <i>Cell Reports</i> , 2018, 25, 3693-3705.e6.	2.9	23
42	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. <i>Blood</i> , 2018, 132, 1050-1063.	0.6	52
43	Genomic patterns of progression in smoldering multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3363.	5.8	163
44	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.	0.6	335
45	Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications. <i>Blood</i> , 2018, 132, 1925-1925.	0.6	0
46	Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control. <i>Blood</i> , 2018, 132, 4500-4500.	0.6	2
47	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. <i>Blood</i> , 2017, 129, 2233-2245.	0.6	33
48	Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. <i>Nature Communications</i> , 2017, 8, 1613.	5.8	45
49	PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2017, 130, 648-648.	0.6	0
50	Biological Insights into Myeloma and Other B Cell Malignancies. <i>BioMed Research International</i> , 2016, 2016, 1-3.	0.9	3
51	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1364-1375.	1.9	94
52	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1364-1375.	1.9	60
53	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	0.6	89
54	Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR γ t, decreases murine spontaneous intestinal tumorigenesis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 13-24.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Deep Response in Multiple Myeloma: A Critical Review. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	32
56	The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , 2015, 21, 572-580.	15.2	79
57	Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition. <i>Blood</i> , 2015, 126, 504-504.	0.6	4
58	Elevated APEX1 Disrupts G2/M Checkpoint, Contributing to Evolution and Survival of Myeloma Cells. <i>Blood</i> , 2015, 126, 2997-2997.	0.6	0
59	Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma. <i>Blood</i> , 2015, 126, 916-916.	0.6	0
60	MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemia. <i>Blood</i> , 2014, 123, 2673-2681.	0.6	16
61	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
62	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014, 124, 3110-3117.	0.6	54
63	Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment. <i>Blood</i> , 2014, 124, 2005-2005.	0.6	1
64	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014, 124, 638-638.	0.6	25
65	Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs). <i>Blood</i> , 2014, 124, 3381-3381.	0.6	1
66	Functional and Clinical Relevance of Splicing Factor SRSF1 in Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 3388-3388.	0.6	0
67	Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma. <i>Blood</i> , 2014, 124, 642-642.	0.6	0
68	Differential and Limited Expression of Mutant Alleles in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2007-2007.	0.6	0
69	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. <i>Blood</i> , 2012, 120, 2932-2932.	0.6	3
70	Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy. <i>Blood</i> , 2012, 120, 1871-1871.	0.6	0
71	Significant Biological Role of Sp1 Transactivation in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 6500-6509.	3.2	47
72	Blockade of XBP1 Splicing by Inhibition of IRE1 α Is a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011, 118, 133-133.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. Blood, 2010, 116, 456-456.	0.6	7
74	Interleukin-17 and TH17 Pathway Supports Waldenstrom's Macroglobulinemia Cell-Growth: Potential Therapeutic Implications. Blood, 2010, 116, 446-446.	0.6	11
75	Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.. Blood, 2009, 114, 1850-1850.	0.6	1
76	Lack of Response to Vaccination in MGUS and Stable Myeloma.. Blood, 2009, 114, 1852-1852.	0.6	11
77	Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.. Blood, 2009, 114, 3848-3848.	0.6	4
78	Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma.. Blood, 2009, 114, 1809-1809.	0.6	0
79	Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.. Blood, 2009, 114, 1789-1789.	0.6	0
80	Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in Vitro and In Vivo.. Blood, 2009, 114, 833-833.	0.6	1
81	Vorinostat Induced Cellular Stress Disrupts the Balance Between p38 MAPK and Erk Pathways Leading to Apoptosis in WM Cells.. Blood, 2009, 114, 3740-3740.	0.6	1
82	CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin.. Blood, 2009, 114, 739-739.	0.6	0
83	Evolution of Genomic Changes and Their Significance in Myeloma.. Blood, 2009, 114, 605-605.	0.6	0
84	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. Blood, 2009, 114, 2846-2846.	0.6	3
85	Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 4785-4785.	0.6	14
86	Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application.. Blood, 2009, 114, 1841-1841.	0.6	0
87	Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).. Blood, 2009, 114, 295-295.	0.6	0
88	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. Nature Precedings, 2008, , .	0.1	2
89	Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease. Blood, 2008, 112, 2739-2739.	0.6	3
90	Sp1 Transcription Factor as a Novel Therapeutic Target in Multiple Myeloma (MM). Blood, 2008, 112, 3664-3664.	0.6	0

#	ARTICLE	IF	CITATIONS
91	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood, 2008, 112, 2737-2737.	0.6	0
92	TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.. Blood, 2007, 110, 3517-3517.	0.6	15
93	Identification of CS1 Peptides for Induction of Antigen-Specific CTLs in Multiple Myeloma.. Blood, 2007, 110, 1611-1611.	0.6	1